Our system expands the use of a PDAC organoid model in translational cancer research for antitumor efficacy and tumor-stroma modulation; quantifications of α-SMA and CK-19 could be used to predict patient clinical outcomes and develop preclinical novel drug trials. Here, KRT19 is linked to neoplasm.